IgG1单稀释亲和力ELISA预测疫苗接种后对异源口蹄疫病毒攻击的交叉保护
研究分析不同血清学检测单独或联合使用能否匹配牛接种口蹄疫病毒(FMDV)疫苗后攻击感染的结果。攻击前21天接种含灭活A Iran 96或A Iran 99病毒株单价制剂的动物血清显示,保护动物IgG1滴度和总IgG亲和力指数显著更高(p < 0.01),IgG2滴度与保护无关(p > 0.05)。开发的IgG1亲和力ELISA一步分析IgG1水平和亲和力,估计保护准确率96%,与攻击结果高度一致(K = 0.85),提示高亲和力IgG1在抗FMDV保护中的作用。
要点
- 保护动物攻击日血清IgG1滴度和总IgG亲和力指数显著高于未保护动物(p < 0.01)。
- IgG2滴度与保护无关(p > 0.05)。
- IgG1亲和力ELISA估计保护准确率96%,与攻击结果高度一致(K = 0.85)。
核心结论
- IgG1单稀释亲和力ELISA可预测FMDV疫苗接种牛的交叉保护,高亲和力IgG1可能发挥保护作用。
研究设计与样本
- 研究使用接种含灭活A Iran 96或A Iran 99病毒株单价制剂21天后的牛攻击日血清,攻击和血清学检测均使用A22 Iraq株。
主要发现
- 保护动物IgG1滴度和总IgG亲和力指数显著高于未保护动物(p < 0.01)。
- IgG2滴度与保护无关(p > 0.05)。
- IgG1亲和力ELISA估计保护准确率96%,与攻击结果高度一致(K = 0.85)。
关键数值与推荐
- 保护动物IgG1滴度和总IgG亲和力指数显著更高(p < 0.01),IgG2滴度与保护无关(p > 0.05)。
- IgG1亲和力ELISA估计保护准确率96%,与攻击结果一致性K = 0.85。
临床怎么用
- 作者认为这些结果支持评估单稀释IgG1亲和力ELISA用于预测FMDV疫苗接种牛的交叉保护。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aims to analyze if the results from different serological assays, used alone or combined, could match the outcome of challenge infection with foot-and-mouth disease virus (FMDV) after vaccination in cattle. Day-of-challenge sera from animals that had been vaccinated 21 days before with monovalent formulations containing inactivated A Iran 96 or A Iran 99 virus strains were used. Challenge and serology were performed with A22 Iraq strain. IgG1 titers and total-IgG avidity indexes were significantly higher in protected animals (p < 0.01) while IgG2-titers were not related to protection (p > 0.05). An IgG1 avidity ELISA was developed to analyze in one step, IgG1 levels and avidity. This assay estimated protection with 96 % accuracy. A strong agreement with challenge results was achieved (K = 0.85), suggesting a role of high-affinity IgG1 in protection against FMDV. These results support the assessment of the single dilution IgG1-Avidity ELISA to predict cross-protection in FMDV-vaccinated cattle.
引用
- Cardoso N, Eschbaumer M, Capozzo AV, et al. An IgG1 single-dilution avidity ELISA predicts cross-protection against heterologous foot-and-mouth disease virus challenge after vaccination. Vaccine. 2024. PMID: 38876835. doi:10.1016/j.vaccine.2024.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。